Related Experiment Video
Updated: Jun 3, 2025

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
Mechanistic insights into GLP-1 receptor agonist-induced weight loss through ceRNA network analysis
Wenxin Li1, Xinyu Zhang2, Jiamin Song1
1Department of Endocrinology and Metabolism, The Affiliated Hospital of Jiangsu University, Institute of Endocrine and Metabolic Diseases, Jiangsu University, Zhenjiang 212000, Jiangsu, China.
Background:
GLP-1 receptor agonists (GLP-1RA) have been extensively utilized in the management of body weight in individuals with obesity. Circular RNA (circRNA), a class of covalently closed RNA molecules, has garnered increasing attention for its potential role in the pathogenesis of obesity. However, the specific mechanisms through which circRNA contributes to GLP-1RA-induced weight loss remains elusive.
Methods:
High-throughput sequencing analyzed epididymal adipose tissue from obese mice under high-fat, and GLP-1RA intervention (600 μg/kg/d). The functions of differentially expressed (DE) genes were enriched and analyzed. The circRNA-miRNA-mRNA interaction network was constructed in Cytoscape, and KEGG pathway gene enrichment was validated via western blotting.
Results:
A total of 644 DEcircRNAs, 186 DEmiRNAs, and 3474 DEmRNAs were identified. Based on ceRNA score calculations, network diagrams were constructed. Gene Ontology (GO) analysis revealed that DERNAs were linked to lipid and fatty acid metabolism. DE genes within ceRNA pairs were enriched in lipid metabolism pathways, especially the PI3K-Akt and AMPK signaling pathways. GLP-1RA induced the phosphorylation of AKT and AMPK, which subsequently led to a reduction of SREBP-1, ACC, and FAS.
Conclusion:
GLP-1RA might activate PI3K-Akt and AMPK signaling pathways to combat obesity through the ceRNA network of circRNAs.
Insights
Glucagon-like peptide-1 receptor agonists (GLP-1RA) may promote weight loss by activating PI3K-Akt and AMPK pathways. This involves a competing endogenous RNA (ceRNA) network of circular RNAs (circRNAs) influencing lipid metabolism in obesity.
Area of Science:
- Molecular Biology
- Genomics
- Metabolic Research
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RA) are established treatments for obesity.
- Circular RNAs (circRNAs) are implicated in obesity pathogenesis.
- The precise role of circRNAs in GLP-1RA-mediated weight loss is not well understood.
Purpose of the Study:
- To investigate the molecular mechanisms by which circRNAs contribute to GLP-1RA-induced weight loss.
- To elucidate the circRNA-miRNA-mRNA regulatory network involved in obesity and GLP-1RA treatment.
Main Methods:
- High-throughput sequencing of epididymal adipose tissue from obese mice treated with GLP-1RA.
- Differential expression analysis of circRNAs, miRNAs, and mRNAs.
- Construction and analysis of a circRNA-miRNA-mRNA competing endogenous RNA (ceRNA) network.
- KEGG pathway enrichment analysis and Western blotting validation.
Main Results:
- Identification of numerous differentially expressed circRNAs, miRNAs, and mRNAs.
- The ceRNA network analysis revealed enrichment in lipid and fatty acid metabolism pathways.
- Key pathways implicated include PI3K-Akt and AMPK signaling.
- GLP-1RA treatment led to increased AKT and AMPK phosphorylation, reducing SREBP-1, ACC, and FAS expression.
Conclusions:
- GLP-1RA may exert anti-obesity effects by activating PI3K-Akt and AMPK signaling pathways.
- This activation appears to be mediated through a circRNA-based ceRNA network.
- These findings provide novel insights into the molecular underpinnings of GLP-1RA action in obesity.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GPCRs Regulate Adenylyl Cylase Activity
Regulation of Food Intake
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Hormonal Regulation
Feedback Loops

